<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of the clinical features, diagnosis, and treatment of the major peroxisomal disorders (excluding X-linked adrenoleukodystrophy and primary hyperoxaluria)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of the clinical features, diagnosis, and treatment of the major peroxisomal disorders (excluding X-linked adrenoleukodystrophy and primary hyperoxaluria)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of the clinical features, diagnosis, and treatment of the major peroxisomal disorders (excluding X-linked adrenoleukodystrophy and primary hyperoxaluria)</div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1">Disorder</td> <td class="subtitle1">Type of disorder (PBD versus single enzyme deficiency)</td> <td class="subtitle1">Gene(s) involved</td> <td class="subtitle1">Clinical features</td> <td class="subtitle1">Age at presentation</td> <td class="subtitle1">Radiographic findings</td> <td class="subtitle1">Initial diagnostic biochemical test</td> <td class="subtitle1">Confirmatory tests</td> <td class="subtitle1">Treatment</td> </tr> <tr> <td>Zellweger spectrum disorders (ZSD)<sup>*</sup></td> <td>PBD</td> <td> <p><em>PEX1</em></p> <p><em>PEX6</em></p> Other <em>PEX</em> genes (uncommon)</td> <td> <ul> <li>Craniofacial dysmorphisms (high forehead, epicanthal folds, hypoplasia of supraorbital ridges and midface)</li> <li>Developmental delay, which can be profound</li> <li>Seizures</li> <li>Hearing and vision impairment</li> <li>Liver disease (hepatomegaly, cholestasis, cirrhosis)</li> <li>Cystic kidney disease</li> <li>Pigmentary retinopathy</li> <li>Cataracts</li> <li>Adrenal insufficiency</li> </ul> </td> <td>Variable; severe forms present in newborn period</td> <td> <ul> <li>Brain MRI may show cortical and white matter abnormalities</li> <li>Skeletal radiographs may show calcific stippling of the epiphyses</li> </ul> </td> <td> <ul> <li>Plasma C26:0-LPC level (where available)<sup>¶</sup></li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Standard plasma VLCFA analysis<sup>¶</sup> (if plasma C26:0-LPC testing is not available)</li> </ul> </td> <td> <ul> <li>Genetic testing<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>No specific treatment; supportive care</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>ACOX1 deficiency</td> <td>Enzyme deficiency</td> <td><em>ACOX1</em></td> <td colspan="3"> <ul> <li>Clinically indistinguishable from ZSD</li> </ul> </td> <td> <ul> <li>Same as for ZSD</li> </ul> </td> <td> <ul> <li>Genetic testing</li> </ul> </td> <td> <ul> <li>No specific treatment; supportive care</li> </ul> </td> </tr> <tr> <td>DBP deficiency</td> <td>Enzyme deficiency</td> <td><em>HSD17B4</em></td> <td colspan="3"> <ul> <li>Clinically indistinguishable from ZSD</li> </ul> </td> <td> <ul> <li>Same as for ZSD</li> </ul> </td> <td> <ul> <li>Genetic testing</li> </ul> </td> <td> <ul> <li>No specific treatment; supportive care</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Rhizomelic chondrodysplasia punctata (RCDP)</td> <td> <p>PBD (RCDP types 1 and 5)</p> Enzyme deficiency (RCDP types 2, 3, and 4)</td> <td> <p>RCDP type 1: <em>PEX7</em></p> <p>RCDP type 2: <em>GNPAT</em></p> <p>RCDP type 3: <em>AGPS</em></p> <p>RCDP type 4: <em>FAR1</em></p> RCDP type 5: <em>PEX5</em></td> <td> <ul> <li>Short stature primarily affecting the proximal long bones (rhizomelia)</li> <li>Global developmental delay, which can be profound</li> <li>Dysmorphic facies</li> <li>Congenital cataracts</li> <li>Ichthyosis</li> <li>Joint contractures</li> </ul> </td> <td>Variable; severe forms present in newborn period</td> <td> <ul> <li>Brain MRI may show white matter abnormalities, pachygyria and polymicrogyria, ventriculomegaly, and/or cerebellar atrophy</li> <li>Skeletal radiographs typically show stippled calcification in long bones and vertebrae</li> </ul> </td> <td> <ul> <li>Erythrocyte plasmalogen analysis</li> </ul> </td> <td> <ul> <li>Genetic testing<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>No specific treatment; supportive care</li> </ul> </td> </tr> <tr> <td>Refsum disease</td> <td>Enzyme deficiency</td> <td><em>PHYH</em></td> <td> <ul> <li>Progressive vision loss due to pigmentary retinopathy</li> <li>Anosmia</li> <li>Sensorineural hearing loss</li> <li>Peripheral neuropathy</li> <li>Ataxia</li> <li>Ichthyosis</li> <li>Cardiac arrhythmias</li> </ul> </td> <td>Adolescence or early adulthood</td> <td> <ul> <li>Brain MRI may be abnormal but there is no characteristic pattern</li> </ul> </td> <td> <ul> <li>Plasma phytanic acid level</li> </ul> </td> <td> <ul> <li>Genetic testing<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>Dietary restriction to eliminate phytol-containing foods</li> <li>Plasmapheresis can be used to rapidly reduce phytanic acid levels in patients with acute severe neurologic symptoms</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes the major peroxisomal disorders, including ZSD, ACOX1 deficiency, DBP deficiency, RCDPs, and Refsum disease. Other major peroxisomal disorders include X-linked adrenoleukodystrophy (X-ALD) and primary hyperoxaluria type 1 (PH1), which are described in detail in separate UpToDate topics and tables. Other rare peroxisomal disorders that have been described in small case series or single case reports include ACOX2 deficiency, AMACR deficiency, BAAT deficiency, ACBD5 deficiency, SCPX deficiency, PMP70 deficiency, and glycolate oxidase deficiency. For additional information, refer to UpToDate's topic on peroxisomal disorders. For information on X-ALD or PH1, refer to separate topics on those conditions.</div><div class="graphic_footnotes"><p>ACBD5: acyl-CoA-binding domain type 5; ACOX1: Acyl CoA oxidase-1; ACOX2: Acyl CoA oxidase-2; AMACR: 2 methylacyl-CoA racemase; BAAT: bile acid-CoA: amino acid N-acyltransferase; C26:0-LPC: C26:0-lysophosphatidylcholine; DBP: D-bifunctional protein; MRI: magnetic resonance imaging; PBD: peroxisome biogenesis disorder; PMP70: peroxisomal membrane protein 70; SCPX: sterol carrier protein-X; VLCFA: very long-chain fatty acid; VUS: variant of uncertain significance; ZSD: Zellweger spectrum disorders.</p>
<p>* ZSD represents a spectrum of disorders that includes classical Zellweger syndrome (the most severe form) and other milder variants. Some conditions included in this category were previously considered separate disorders (eg, neonatal adrenoleukodystophy [NALD] and infantile Refsum disease [IRD]). However, since NALD and IRD are caused by the same genetic variants as ZSD (<em>PEX1</em> and <em>PEX6</em>) with a similar constellation of clinical and laboratory findings, they are now considered part of ZSD.</p>
<p>¶ If plasma C26:0-LPC or VLCFA analysis is abnormal, additional testing is performed in the same blood sample, including analysis of peroxisomal biomarkers in plasma (bile acid intermediates, phytanic acid, pristanic acid, pipecolic acid) and peroxisomal biomarkers in erythrocytes (plasmalogens).</p>
Δ Additional confirmatory testing with functional assays using fibroblasts can sometimes be useful in the diagnostic evaluation for these disorders (eg, if genetic testing identifies a VUS).</div><div id="graphicVersion">Graphic 142994 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
